Dr. Petros Grivas, MD at Cleveland Clinic discusses the evaluation of response to enzalutamide consecutively after disease progression on abiraterone prednisone at ASCO GU 2016 in San Francisco.
Author: admin
Dr. Petros Grivas, MD of Cleveland Clinic discusses The association of D4, 3-keto-abi (D4A) and response to abiraterone in castration-resistant prostate cancer (CRPC) from ASCO GU 2016.
Dr. Walter Stadler of The University of Chicago Cancer Center @UCCancerCenter discusses Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC at ASCO GU 2016
“Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukaemia (CLL) cells and the common side-effects experienced by these drugs. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.”
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of venetoclax (ABT-199) for the treatment of chronic lymphocytic leukemia (CLL), as a single-agent and in combination with other therapies. Peter Hillmen discusses two studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting. These clinical trials study the use of venetoclax with rituximab and venetoclax with obinutuzumab.
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of the Resonate-2 clinical trial of ibrutinib vs. chlorambucil as front-line therapy, in patients unfit for fludarabine, cyclophosphamide, rituximab (FCR) therapy. The Phase III results presented at the American Society of Hematology (ASH) 2015 Annual Meeting, show that 98% of patients in the ibrutinib arm have a progression free survival period longer than 2 years.
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase Ib study of venetoclax (ABT-199) and obinutuzumab, an anti-CD20 antibody, in relapsed/refractory or previously untreated chronic lymphocytic leukaemia (CLL). The preliminary data show patients achieving minimum residual disease (MRD) states with no toxicity.
Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 96% of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.
Jacqueline Barrientos, MD, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.
Jacqueline Barrientos, MD, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides details of a current trial comparing two treatments that work on different pathways (PI3K and BTK B-cell inhibitors), with the goal of understanding the best salvage options following treatment failure.
Jacqueline Barrientos, MD, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that had no post-trial access to ibrutinib, or those who moved to a comparator. The insights from this study help to inform decisions regarding sequential and salvage treatments.
Dr. Walter Stadler of the University of Chicago discusses how Checkpoint inhibitors iwill mpact outcomes for advanced RCC
Dr. Walter Stadler discusses his experience with FDA approved Nivolumab and PD-1 and PD-L1 inhibitors in RCC
Patient Power founder Andrew Schorr along with patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) meeting sit down with Dr. Jennifer Cultrera to discuss the progress in treating follicular lymphomas. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
How far have we progressed in the field of CLL research? Patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) meeting, visited with leading CLL expert Dr. Richard Furman to hear his perspective on news from the conference. Listen as Dr. Furman gives a rundown of last years novel agents and todays best possibility for deep remission. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Is there hope for people with Hodgkin Lymphoma? Dr. John Sweetenham, Executive Medical Director of the Huntsman Cancer Institute, says, Yes! On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) conference, Andrew Schorr visits with Dr. Sweetenham to discuss emerging agents and monitoring strategies for patients with Hodgkin lymphoma. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Are clinical trials still valid as a means for treatment? On location at the 2015 American Society of Hematology (ASH), Medical Correspondent, Carol Preston, speaks with myeloma expert Dr. Sagar Lonial, Chief Medical Officer at Winship Cancer Institute of Emory University, about the rapidly changing therapies for multiple myeloma patients. Listen as Dr. Lonial makes a strong statement for clinical trials as the catalyst for a cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma.
Watch patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) conference, discusses the new molecule, ACP-196, a second-generation BTK inhibitor, with CLL expert Dr. Kathryn Kolibaba. Dr. Kolibaba describes this new molecules function including its potential for decreased side effects and her hopes for the future. Never, exclaims Dr. Kolibaba, have we had a better menu of options. Never have we had hope like we do now for a cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
As part of our coverage of the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naveen Pemmaraju from MD Anderson Cancer Center joined Patient Power to discuss social media and hematology, focusing on a well-attended session from the meeting. Dr. Pemmaraju expands on the benefits of using social media to educate patients as well as potential issues with this form of communication. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Lymphoma expert Dr. Jeff Sharman, on location at 2015 American Society of Hematology (ASH) meeting, reviews the advancement of follicular lymphomas (non-Hodgkin lymphomas) as they rapidly progress towards becoming a chronic condition. Watch as Dr. Sharman extends hope to patients through use and understanding of clinical trials. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the 2015 American Society of Hematology (ASH) conference, patient advocate Carol Preston and Dr. Christopher Yasenchak, from US Oncology Research, discuss encouraging news for Hodgkin lymphoma patients who are over 60 years old. Dr. Yasenchak explains why 50 percent of older patients cannot tolerate current potent chemo side effects and the exciting new combination treatments in pre-clinical trial that offer, as Dr. Yasenchak says a game-changing opportunity. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Endocrine therapy may cause many bothersome side effects, often affecting a patients compliance. Dr Naughton suggests BCI as a tool to objectively help patients understand their likelihood of benefit and help encourage them to continue therapy, if appropriate. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
Is there current research for the 20 percent of CML (Chronic Myelogenous Leukemia) patients who are resistant to imatinib mesylate (Gleevec)? CML expert Dr. Kathryn Kolibaba answers with an emphatic Yes!. Patient advocate Carol Preston speaks with Dr. Kolibaba as they discuss various studies directed at improving quality of life and managing Gleevec-resistant patients. The data is very, very promising, reports Dr. Kolibaba. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Patient Power founder caught up with leading CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH) meeting to hear his perspective on CLL news from the conference. Watch as Dr. Kipps reviews data, including the use of ibrutinib (Imbruvica) in the frontline setting, the role of chemotherapy and an update on emerging therapies. Sponsored by the Patient Empowerment Network through educational grants from Teva and Pharmacyclics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Are clinical trials still a good idea for patients? Is there still a place for chemo? Who should get genetic testing and when should it be done? Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center answers in-depth questions about CLL on location in Orlando, Florida at the 2015 American Society of Hematology (ASH). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the 2015 American Society of Hematology (ASH) annual meeting, myeloma expert Dr. James Berenson joined Patient Power to discuss the recent wave of approvals for the treatment of multiple myeloma. Dr. Berenson speaks about the range of new therapies, discussing monoclonal antibodies, proteasome inhibitors and many others, including where each of these treatments fit into patient care. He also discusses potential issues with patient compliance, the cost of treatment and the path to cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
What is the REVEAL study, and why is it so important to polycythemia vera (PV) patients? On location at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Brady Stein from Robert H. Lurie Comprehensive Cancer Center discusses the demographics and benefits of the study. Dr. Stein is particularly hopeful with the new developments and sophisticated prognosis being applied to PV. You can learn more about the REVEAL study at revealpvstudy.com. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
CLL expert Dr. Jeff Sharman, on location at the ASH (American Society of Hematology) 2015 meeting, Dr. Jeff Sharman, shares the latest in CLL research news. Listen as Dr. Sharman explains in detail the expected outcomes of the RESONATE Phase III trial, as well as the ongoing research on ABT-199. When asked if he is hopeful, Dr. Sharman responds with an enthusiastic, Oh, gosh, yeah!…The statistics aren’t real anymore.CLL patients are living much more normal lives Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ |…
As part of Patient Power coverage from the 2015 American Society of Hematology (ASH), myeloma experts Dr. Noopur Raje, Dr. John Burke and Dr. Faith Davies, along with myeloma patient advocate Jack Aiello, gathered to discuss the latest news and research in multiple myeloma. The experts reviewed the recent approval of three new treatments, data presented on the power of combination therapy, important suggestions regarding prognosis and testing, and plenty of encouraging news based on presentations from the meeting. Each guest shares specific advice to myeloma patients to help them get the best care possible. Get email alerts | http://www.patientpower.info/alerts…
As part of our coverage of the 2015 American Society of Hematology annual meeting, MPN expert Dr. Richard Silver joined Patient Power to discuss interferon therapy for the treatment myeloproliferative neoplasms (MPNs), specifically myelofibrosis and polycythemia vera. Dr. Silver explains interferon, how it works, and the potential benefits of small doses of interferon therapy for MPNs. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Dr. Zeev Estrov, of MD Anderson Cancer Center, discusses fatigue in CLL patients including findings from ongoing research on JAK2 inhibitors and the encouraging news regarding reported symptom improvements. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Breast Cancer Index (BCI) validation studies included both women treated with aromatase inhibitors (AI) and women treated with tamoxifen (Tam). The three validation studies included patients treated with Tam only (Stockholm), either anastrozole or Tam (ATAC), and Tam with a transition to letrozole (MA.17). For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
As part of our coverage of the 2015 American Society of Hematology annual meeting, myeloma expert Dr. Paul Richardson joined Patient Power to discuss this years approvals for the treatment of multiple myeloma, which includes seven total agents. Dr. Richardson reviews each of the treatments and shares how these new therapies work and how they impact multiple myeloma survival. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Patient Power founder Andrew Schorr led an expert panel as they reviewed CLL news from the 2015 American Society of Hematology (ASH) meeting in Orlando. Watch as Drs. John Gribben, Constantine Tam and William Wierda explore the full gamut of developing treatment approaches. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
As part of our coverage from the 2015 American Society of Hematology (ASH), a panel of MPN experts including Dr. Laura Michaelis, Dr. Ruben Mesa, Dr. Bart Scott and our own Andrew Schorr gathered to discuss the latest news and research in myeloproliferative neoplasms (MPNs). The experts discussed the changing treatment landscape in the field, their individualized approaches to treating MPN patients, and shared encouraging perspectives about current and future developing research. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naval Daver of MD Anderson Cancer Center speaks candidly regarding the future of myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) research and treatment. Dr. Daver discusses the increasing value of genetic analysis as well as the push to find new drugs to defeat markers and mutations. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the European Cancer Congress (ECC) 2015, Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of IMvigor 210, a multicentre, phase 2 clinical trial that was designed to evaluate the efficacy and safety of atezolizumab, an anti-PD-L1 antibody, in patients with locally-advanced or metastatic urothelial carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rachael Crayton, Oncology Specialist Nurse from Central Manchester NHS Foundation Trust, Manchester, UK, discusses the key themes from a networking exercise with cancer survivorship programmes in the UK and USA that may be used to enhance these services for patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Patient Power founder Andrew Schorr talks with MPN expert Dr. Srdan Verstovsek to reflect on the final days of the 2015 American Society of Hematology (ASH) meeting. Andrew and Dr. Verstovsek discuss the importance of a second opinion and specialized care. Learn why Dr. Verstovsek is excited about evolving research and the advances and hope of the near future. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Watch coverage from the 2015 American Society of Hematology (ASH) meeting with myeloma expert Dr. Robert Orlowski from MD Anderson Cancer Center as he joined Patient Power to answer questions from Patient Power community members. Dr. Orlowski answered a variety of questions and shared his thoughts on the latest news and research being shared at this years meeting. This program is sponsored by the Patient Empowerment Network through educational grants from Celgene, Novartis and Takeda. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Renowned CLL expert Dr. Jeff Sharman answered your questions LIVE, as we broadcasted from the 2015 American Society of Hematology (ASH) meeting. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
From ASH 2015, patient advocates Andrew Schorr and Carol Preston are joined by myeloma specialist Dr. Gareth Morgan as they discuss the latest news. The panel discusses research highlights and the importance of being an informedand empoweredpatient. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Patient advocates and hosts Andrew Schorr and Carol Preston review the highlights from the first few days of the 2015 American Society of Hematology (ASH) meeting. Andrew and Carol are joined by Dr. Jennifer Brown, a leading CLL researcher, who shares her perspective on the role of genetics in treating CLL and her advice for getting the best care. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the American Society of Hematology (ASH) meeting in Orlando, CLL expert Dr. Jan Burger discussed the result from the RESONATE-2 trial, which studied the use of ibrutinib (Imbruvica) vs. chlorambucil in the frontline setting in patients over 65. Dr. Burger reviews the medications benefits in overall survival, progression free survival, and in response rates. Learn why Dr. Burger feels it is compelling to use ibrutinib more in the frontline setting for elderly patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the evidence requirements for the clinical development of prognostic and predictive genomic tests for individual risk stratification and adjuvant treatment selection in breast cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews This content is supported by Genomic Health, Inc.
The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma
In the era of molecular medicine, there is now a tool called Breast Cancer Index (BCI) to help physicians determine whether to recommend extended endocrine therapy.
The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma